Across its top 20 institutional holders, PCRX's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 6/100, avg. turnover score 26/100).
Quarterly Activity
Recent Activity
+$370.2M
Total Buy Value
$640.1M
Total Sell Value
New buy23
Trim85
Add89
Sold out45
112
Net Buyers
130
Net Sellers
Smart Money Convergence
PCRX does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.
13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.
Insider Trading (Form 4)
Form 144 Pre-Sale Notices
3
Filings (90d)
$583K
Total Est. Value
25K shares
Planned Shares
Last Filed 2026-06-12
Filer
Title/Relationship
Filing Date
Planned Shares
Est. Value
Ceesay Abraham
Director
2026-06-12
9K shares
$210K
RIKER LAUREN
Officer
2026-06-11
6K shares
$144K
WILLIAMS KRISTEN
Officer
2026-06-04
10K shares
$228K
Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。
Beneficial Ownership (13D/13G)
No Schedule 13D/13G filings for this ticker
Material Events (8-K)
1
Filings (14d)
Data as of 2026-06-30
2026-06-30
Pacira BioSciences has agreed to sell its subsidiary Pacira CryoTech and its handheld cryoanalgesia devices (including iovera®) to Zimmer Biomet's subsidiary for up to $140 million, including $70 million upfront and up to $70 million in milestones based on future revenue. The deal is expected to close in the third quarter of 2026. About 66 employees, representing 8% of Pacira's workforce, are expected to be hired by the buyer.
Who are the top institutional investors holding PACIRA BIOSCIENCES INC (PCRX)?
Major stakeholders currently include BlackRock, Inc. ($152.2M), Doma Perpetual Capital Management LLC ($62.8M), Vanguard Portfolio Management LLC ($56.5M). Based on the latest 13F filings, there are a total of 239 tracked investment funds and institutions maintaining positions in PCRX.
What is the overall institutional sentiment toward PCRX recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $229.5M, driven by 112 managers accumulating shares while 130 reduced their exposure.
Which institutions have been selling or reducing their PCRX positions?
In the latest period, 85 funds trimmed their holdings, and 45 managers completely exited their positions. The aggregate reported sell value was $640.1M.
Are there any notable investors adding PCRX to their portfolios?
Yes, buying activity remains notable. 23 institutions opened new positions in {ticker}, and 89 existing holders added to their shares. The total reported buy value for the quarter amounted to $370.2M.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter